3-羧基-4-甲基-5-戊基-2-呋喃丙酸 | 73248-95-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 3-羧基-4-甲基-5-戊基-2-呋喃丙酸
• 中文别名: 2-[(8-甲基壬基)氧代]乙醇
• 英文名称: Pentylurofuransaeure
• 英文别名: 2-(2-carboxyethyl)-4-methyl-5-pentylfuran-3-carboxylic acid；3-carboxy-4-methyl-5-pentyl-2-furanpropanoic acid；3-Cmpfp
• CAS: 73248-95-0
• 化学式: C₁₄H₂₀O₅
• 分子量: 268.31
• InChiKey: RIJDKRLRDVBUHJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  19
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  87.7
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  重氮甲烷 、 3-羧基-4-甲基-5-戊基-2-呋喃丙酸 在 盐酸 作用下， 以 乙醚 为溶剂， 生成 methyl 2-(3-methoxy-3-oxopropyl)-4-methyl-5-pentylfuran-3-carboxylate
  参考文献：
  名称：

  Spiteller, Michael; Spiteller, Gerhard; Hoyer, Georg-Alexander, Chemische Berichte, 1980, vol. 113, # 2, p. 699 - 709

  摘要：

  DOI：
• 作为产物：
  描述：

  在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 1.0h， 以88%的产率得到3-羧基-4-甲基-5-戊基-2-呋喃丙酸
  参考文献：
  名称：

  尿呋喃酸的合成与表征：2-（2-羧乙基）-4-甲基-5-丙基呋喃-3-羧酸（CMPF）的体内代谢及其对胰岛素分泌的影响

  摘要：

  CMPF（2-（2-羧乙基）-4-甲基-5-丙基呋喃-3-羧酸）是一种代谢产物，在2型和妊娠糖尿病患者中以高浓度循环。此外，人类临床研究表明它可能在这些疾病中起因果作用。CMPF在啮齿动物中体外和体内抑制小鼠和人类胰岛中的胰岛素分泌。但是，尚未对CMPF的代谢命运以及结构与胰岛素分泌的影响之间的关系进行研究。描述了CMPF及其类似物的合成。这些包括同位素标记的分子。在体内对这些材料的研究导致首次观察到CMPF的代谢产物。另外，已经制备了多种CMPF类似物，并在使用小鼠和人胰岛的胰岛素分泌测定中对其进行了表征。鉴定了几种影响体外胰岛素分泌的分子。描述的分子应作为进一步研究CMPF生物学的有趣探针。

  DOI：

  10.1021/acs.jmedchem.6b01668

文献信息

• THERAPEUTIC SYSTEMS USING MAGNETIC FIELDS
  申请人：University of Iowa Research Foundation

  公开号：US20210052910A1

  公开（公告）日：2021-02-25

  A system may comprise one, two or more magnetic field systems. The magnetic field system may be configured to provide a magnetic field in a first direction to the tissue. The magnetic field system may include at least one magnetic field source to produce the magnetic field. The magnetic field produced by the at least one magnetic field source may include a magnetic field produced by at least one of a permanent magnet, a temporary magnet or electric current flow through a conductor. The same or a second magnetic field system may be configured to provide a second magnetic field in a second direction to the tissue. The magnetic field system may include two or more sources to provide the magnetic field in a second, third or fourth direction that is non-parallel to the first direction.
• MONITORING EFFICACY OF MAGNETIC AND ELECTRIC FIELDS USING BIOMARKERS
  申请人：University of Iowa Research Foundation

  公开号：US20220118269A1

  公开（公告）日：2022-04-21

  An example may deliver a therapy by delivering energy to tissue. A method may include delivering energy to the tissue by providing a magnetic field in a first direction to the tissue using a magnetic field system including a magnetic field source to produce the magnetic field, wherein the magnetic field produced by the magnetic field source includes a magnetic field produced by at least one of a permanent magnet, a temporary magnet or electric current flow through a conductor, and providing an electric field in a second direction to the tissue using an electric field system including an electric field source to produce the electric field, wherein the second direction is non-parallel to the first direction. The method may further include detecting biomarker(s) within at least one of a redox system and a metabolic system to monitor efficacy of the therapy and/or calibrate or adjust the therapy.
• [EN] FURAN FATTY ACID BIOMARKERS OF NUTRITIONAL STATUS<br/>[FR] BIOMARQUEURS DE L'ÉTAT NUTRITIONNEL D'UN SUJET BASÉS SUR DES ACIDES GRAS FURANIQUES
  申请人：AFEKTA TECH OY

  公开号：WO2018042072A1

  公开（公告）日：2018-03-08

  A method for assessing or aiding in the assessment of a nutritional status or the effectiveness of a nutritional regimen in a subject is disclosed, the method comprising analyzing a biological sample from the subject to determine the level (s) of at least one furan fatty acid in the sample; and comparing the level (s) in the sample to a reference value or to a control sample in order to assess the nutritional status or the effectiveness of the nutritional regimen in the subject.
• Spiteller, Michael; Spiteller, Gerhard; Hoyer, Georg-Alexander, Chemische Berichte, 1980, vol. 113, # 2, p. 699 - 709
  作者：Spiteller, Michael、Spiteller, Gerhard、Hoyer, Georg-Alexander

  DOI：——

  日期：——
• Synthesis and Characterization of Urofuranoic Acids: In Vivo Metabolism of 2-(2-Carboxyethyl)-4-methyl-5-propylfuran-3-carboxylic Acid (CMPF) and Effects on in Vitro Insulin Secretion
  作者：Edith Nagy、Ying Liu、Kacey J. Prentice、Kyle W. Sloop、Phillip E. Sanders、Battsetseg Batchuluun、Craig D. Hammond、Michael B. Wheeler、Timothy B. Durham

  DOI：10.1021/acs.jmedchem.6b01668

  日期：2017.3.9

  -carboxylic acid) is a metabolite that circulates at high concentrations in type 2 and gestational diabetes patients. Further, human clinical studies suggest it might have a causal role in these diseases. CMPF inhibits insulin secretion in mouse and human islets in vitro and in vivo in rodents. However, the metabolic fate of CMPF and the relationship of structure to effects on insulin secretion have

  CMPF（2-（2-羧乙基）-4-甲基-5-丙基呋喃-3-羧酸）是一种代谢产物，在2型和妊娠糖尿病患者中以高浓度循环。此外，人类临床研究表明它可能在这些疾病中起因果作用。CMPF在啮齿动物中体外和体内抑制小鼠和人类胰岛中的胰岛素分泌。但是，尚未对CMPF的代谢命运以及结构与胰岛素分泌的影响之间的关系进行研究。描述了CMPF及其类似物的合成。这些包括同位素标记的分子。在体内对这些材料的研究导致首次观察到CMPF的代谢产物。另外，已经制备了多种CMPF类似物，并在使用小鼠和人胰岛的胰岛素分泌测定中对其进行了表征。鉴定了几种影响体外胰岛素分泌的分子。描述的分子应作为进一步研究CMPF生物学的有趣探针。